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AbstrACt
Introduction Patients with severe dry eye disease (DED) 
often have limited treatment options with standard non-
surgical management focused on the use of artificial tears 
for lubrication and anti-inflammatory drugs. However, 
artificial tears do not address the extraordinary complexity 
of human tears. Crudely, human tears with its vast 
constituents is essentially filtered blood. Blood and several 
blood-derived products including autologous serum, have 
been studied as tear substitutes. This study proposes to 
test the use of whole, fresh, autologous blood obtained 
from a finger prick for treatment of severe DED. 
Methods and analysis The research team at the two 
participating sites will approach patients with severe 
DED for this study. Recruitment will take place over 12 
months and we expect to recruit 60 patients in total. The 
primary outcome of this feasibility study is to estimate the 
proportion of eligible patients approached who consent 
to and comply with study procedures including treatment 
regimen and completion of required questionnaires. The 
secondary outcome measures, although not powered for 
in this feasibility, include corneal inflammation (assessed 
by the Oxford corneal staining guide), patient pain and 
symptoms scores (assessed by the Ocular Surface 
Disease Index Score), and objective signs of DED as 
indicated by visual acuity (assessed by Schirmer’s test, 
tear break-up time, lower and/or upper tear meniscus 
height measurement). Other secondary outcomes include 
patients’ quality of life (assessed using the validated EQ-
5D-5L Questionnaire), cost to the National Health Service 
(NHS) and patient (assessed via use of NHS services and 
privately purchased over-the-counter treatment related 
to DED) and safety measure of pressure within the eye 
(assessed by the Intraocular Pressure (IOP) Score).
Ethics and dissemination This protocol and any 
subsequent amendments, along with any accompanying 
material provided to the participant in addition to any 
advertising material used in this trial have been approved 
by the East of England - Cambridgeshire and Hertfordshire 
Research Ethics Committee (REC reference: 17/EE/0508). 
Written approval from the committee was obtained and 
subsequently submitted to the respective Trust’s Research 
and Development (R&D) office with final NHS R&D approval 
obtained. Data obtained from this study will be published 
in a suitable peer-review journal and will also presented 
at international ophthalmic conferences including the 
American Academy of Ophthalmology, the Royal College 
of Ophthalmology Annual Congress, the Association for 
Research and Vision and Ophthalmology, and the European 
Society of Cataract and Refractive Surgery. Information will 
be provided to patient groups and charities such as the 
Sjogren's Society and the Royal National Institute of Blind 
People. This will also be shared with the study participants 
as well as with relevant patient groups and charities.
trial registration number NCT03395431; Pre-results.
IntroduCtIon
Dry eye disease (DED) is an umbrella term 
encompassing a range of ocular diseases 
estimated to affect 14% of all adults aged 
48–91 years.1 If left untreated, DED can 
lead to severe reduction in the quality of life 
(QoL) of the patient. It can also cause loss 
of vision, pain in response to light, painful 
strengths and limitations of this study
 ► This single-blind randomised control trial address-
es a significant problem by investigating the use 
of whole, fresh, autologous blood obtained from a 
finger prick for treatment of severe dry eye disease.
 ► The study intervention is cheap, simple and with 
minimal risk of complication.
 ► The intervention will allow for the delivery of the 
beneficial components of tears including growth 
factors and proteins found in whole blood.
 ► Patients in the intervention arm may experience 
soreness in fingers that are repeatedly pricked and 
will be advised to use a different finger for each eye.
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recurring stabbing sensations and the feeling of grit in 
the affected eye(s). Studies show that moderate-to-severe 
DED can be as disruptive to patient QoL as angina.2 3 
Despite this, only less than 2% of all UK medical research 
funding is directed at diseases of the eye, leaving eye 
research critically underfunded.4 No curative agents 
for DED exist. The treatment of the disorder is essen-
tially symptomatic with standard non-surgical treatment 
focused on the use of artificial tears for lubrication and 
anti-inflammatory drugs.
Anti-inflammatory agents used in DED include topical 
steroids and ciclosporine drops but these can cause side 
effects that limit their long-term use.5 Topical steroids can 
also cause cataracts and glaucoma, all of which further 
limit their use. Surgical options for DED include punctal 
occlusion to reduce tear drainage, punctal cauterisation 
(burning the drainage channel of tears and preventing 
their outflow) and partial suturing of the eyelids. However, 
these treatment options are associated with adverse effects 
and varying levels of patient tolerability. Overall, available 
conventional treatment options for DED often only alle-
viate symptoms, have limited effectiveness, and in most 
cases patients may fail to respond—although the exact 
rate of treatment failure is unavailable in the published 
literature.
The mainstay of non-surgical treatment for DED focuses 
on the use of artificial tears. These can be purchased over 
the counter and include brand name products such as 
Viscotears and Optrex.6 Human tears contain an extensive 
range of growth factors, immunoglobulins, enzymes, cyto-
kines, vitamins and electrolytes and these have been shown 
in numerous studies to be essential for the maintenance and 
proliferation of corneal epithelial cells as well as for defence 
against infection.7 It is well known that artificial tears fail 
to account for the extraordinarily complex composition 
of the natural tear film. Also, many artificial tears contain 
preservatives that have been shown to adversely affect the 
cornea.8 Crudely, the human tear with its vast constituents 
is essentially filtered blood and as such is an obvious source 
for a ‘tear mimic’ containing all tear constituents. Blood 
and several blood-derived products including autologous 
serum (AS) have been studied as tear substitute candidates.
AS eye drops have been found to be beneficial in 
uncontrolled trials by improving the ocular surface and 
reducing symptoms.9–11 However, a Cochrane review 
concluded that there is inconsistency in evidence on its 
benefit.12 Obtaining AS requires frequent drawing of 
blood from the patient—a feature that excludes patients 
with anaemia or heart failure from using AS. Furthermore 
it also appears that 100% AS is more beneficial than 50% 
serum and requires larger volumes of blood and/or more 
frequent venesection.10 Patients using AS also require 
access to a fridge, as the product needs to be stored at low 
temperatures—a factor that is likely to be inconvenient 
for patients. In addition, AS is obtained by processing 
clotted blood at an initial cost of £1653.56 to the National 
Health Service (NHS), and subsequent 3-monthly costs of 
£1131.27 per patient.
The relatively high cost represents the biggest hurdle 
in the use of AS and is often the reason for delay or inac-
cessibility in its use as a treatment for DED. We propose 
that finger prick autologous blood (FAB) is a simpler, 
cost-effective and possibly more acceptable method for 
treating DED. For this reason, this study proposes to test 
the use of FAB in which blood obtained from a small 
finger prick is applied to the eye. Autologous fresh blood 
is already being used in the subconjunctiva to help heal 
leaking trabeculectomy blebs.13–16 It is also used to help 
attach limbal autografts in cases of pterygium,17 and in 
vitreoretinal macular hole surgery18–21 with no adverse 
effects reported. The FAB method can be used in patients 
who are awaiting conventional treatment for autologous 
blood.
rationale and risks/benefits
This study proposes to test the feasibility of the use of 
whole, fresh, autologous blood as a treatment for severe 
DED (detailed study protocol presented as online supple-
mentary file). The blood can be obtained from a clean 
finger, pricked by the patient using a diabetic lancet 
and administered immediately to the eye. This allows 
the delivery of most of the aforementioned beneficial 
components of tears and additional growth factors and 
proteins, fresh and unprocessed, which can help heal 
the ocular surface. If validated, this may replace current 
AS practice and with its ease of use, vastly reduced cost 
and greater convenience may mean that it could be 
extended to other ocular surface diseases. The proposing 
team have completed an exploratory study on the use of 
FAB for persistent epithelial defects and severe DED and 
preliminary results indicate improvement with no adverse 
events (AEs) reported.22 The exploratory study included 
16 patients with a diagnosis of severe-to-moderate dry eye 
syndrome and used the FAB method for treatment. The 
findings of the study demonstrated mean improvements in 
visual acuity, Oxford corneal staining grade, tear break-up 
time and DED questionnaire score. The response rate 
from participants was good with only a single patient who 
met the inclusion criteria not wishing to participate in 
the trial. Both the amount of staining (indicating inflam-
mation and ocular surface damage) and their DED ques-
tionnaire scores (indicating severity of their symptoms 
and impact on QoL) showed mean improvement which 
reached statistical significance. A search of clinical data-
bases (Medline, CINAHL and AMED) including ongoing 
trials on the UKCRN (UK Clinical Research Network) 
portfolio database and related websites (www. controlled- 
trials. com) did not identify any studies using FAB as a 
treatment for DED.
PrIMAry And sECondAry objECtIvEs
The primary objective is to determine the feasibility of a 
definitive randomised controlled trial (RCT) to evaluate 
effectiveness of the use of fresh autologous blood (FAB) 
compared with conventional treatment for patients with 
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severe dry eye syndrome. The primary outcome is the 
proportion of eligible patients approached who consent 
to and comply with study procedure including treatment 
regimen and completion of required questionnaires. The 
secondary objectives, although not powered for within this 
feasibility include: to estimate the effectiveness of the trial 
intervention and further explore the acceptability of the 
study design, and to explore the feasibility of collecting 
resource use and QoL data to inform the design of the 
health economics component of a future definitive trial. 
The secondary outcome measures, although not powered 
for within this feasibility, include corneal inflammation 
(assessed by the Oxford Corneal Staining Guide), patient 
pain and symptoms scores (assessed by the Ocular Surface 
Disease Index (OSDI) Score) and objective signs of DED 
as indicated by visual acuity (assessed by Schirmer’s test, 
tear break-up time, lower and/or upper tear meniscus 
height measurement). Other secondary outcomes 
include patients’ QoL (assessed using the validated 
EQ-5D-5L Questionnaire), cost to the NHS and patient 
(assessed via use of NHS services and privately purchased 
over-the-counter treatment related to dry eye disease) 
and safety measure of pressure within the eye (assessed by 
the Intraocular Pressure (IOP) Score).
MEthod
study design
This is a single blind, two-arm feasibility RCT of FAB with 
conventional treatment versus conventional therapy alone 
for severe DED, including a qualitative process evaluation 
(figure 1 provides details of the study scheme). This trial 
is ongoing and open to recruitment at two participating 
sites: Bedford Hospital NHS Trust and Moorfields Eye 
Hospital London. Recruitment into the trial commenced 
in April 2018 and is due to finish by April 2019.
sample size
As this is a feasibility trial, there were no formal sample 
size calculations.23 The aim of the study is to recruit a suffi-
cient number of patients to evaluate the acceptability and 
feasibility of the intervention. An outcome of this study 
will be to estimate parameters such as the SD for a sample 
size calculation of a subsequent full-scale trial. A sample 
of 52 patients (26 in each arm) is considered adequate for 
obtaining reliable sample size estimates.24 25 To allow for 
a conservative attrition rate of 10%, we aim to recruit 60 
patients into the trial.
Participant selection
Inclusion criteria
 ► Patient age ≥18 years.
 ► Severe symptomatic DED diagnosed by: OSDI Score 
>33; or Oxford corneal staining grade ≥2; or Schirm-
er's test without anaesthesia <5 mm at 5 min.
 ► Patients on artificial tears and/or lubricating drops/
gel four times a day.
 ► Patient able to give consent.
 ► Patients able and willing to complete the QoL Ques-
tionnaires required for the study.
Exclusion criteria
 ► Fear of needles.
 ► Unable or not willing to carry out repeat finger pricks.
 ► Patients with infected finger/s or systemic infection 
or on systemic antibiotics for infection.
 ► Patients with active ocular infection, active immuno-
logical corneal melt or recurrent corneal erosion.
 ► Pregnant or breastfeeding women.
 ► Previous use of FAB treatment (eg, from exploratory 
study).
 ► Systemic illness causing immune system deficiency.
 ► Graft versus host disease.
 ► Previous use of AS within 3 months.
 ► Diabetes.
Intervention
Arm A—FAB plus conventional treatment
The patients will use FAB therapy alongside conventional 
therapy (artificial tears, ciclosporine drops or punctal 
plugs/cautery) as recommended by their treating 
ophthalmologist. Hands will be washed with soap and 
water, dried and then a fingertip of the hand will be 
wiped with an alcohol-based wipe and self-pricked using 
a standard diabetic lancet. The drop of blood produced 
as normal is applied to the lower fornix of the affected 
eye(s) with the lower lid pulled down slightly by the 
patient. The blood will be applied four times a day. A 
fresh finger will be used for each eye and blood wiped 
away with the alcohol-based wipe. Patients will be advised 
to keep nails short and to avoid nail varnish. The FAB 
intervention will be applied at least 15 min after any artifi-
cial tears and participants must not use drops for at least 
half an hour after this.
Arm B—conventional treatment only
The patients will use conventional therapy (artificial 
tears, ciclosporine drops and punctal plugs/cautery) as 
recommended by their treating ophthalmologist.
Qualitative approach
A nested qualitative approach using in-depth, semistruc-
tured interviews will help us understand the lived experi-
ence of people using FAB and factors relating to the ways 
that clinical departments and healthcare professionals 
adapt to working with FAB. Topics, questions and probes 
in the interviews will emerge from three sources: the rele-
vant literature; our experience of and involvement in 
clinical ophthalmology; and consultation with patients. In 
this feasibility study, we will use a convenience sampling 
technique for the qualitative work. We will interview all 
clinicians who administer the intervention in the study 
and we will aim to interview 10 patients (adjusted for 
setting, gender and age group representation). Given 
the resources, we will aim to draw findings from a larger 
sample in a future study. This phase will work in parallel to 
the quantitative data collection so that emerging themes 
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can be investigated in later interviews. Even though the 
feasibility study sample is reasonably limited, we antici-
pate some useful insights about the use of FAB because 
of the triangulation between the RCT and the qualitative 
findings (for example, reasons for partial adherence).
Economic evaluation
Good practice recommendations for cost-effectiveness 
analyses suggest concentrating on the measurement of 
large cost drivers, with less focus on resources that are not 
expected to differ between different treatments.26 Estima-
tion of cost-effectiveness is therefore an iterative process 
and by including a health economic component in the 
feasibility it is possible to consider how the methods 
might be refined in any future definitive study. In order 
to estimate costs, informed by previous data collection 
instruments (Database of Instruments for Resource Use 
Measurement: http://www. dirum. org/) and National 
Institute for Health and Care Excellence  guidance,27 a 
Figure 1 Study scheme. FAB, fresh autologous blood .
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self-report resource use questionnaire will be devised. 
This will capture the use of NHS services and privately 
purchased over-the-counter treatments such as Optrex. 
For benefits, EQ-5D-5L28 will be used to measure QoL, 
enabling quality-adjusted life year scores to be calculated. 
The main purpose of the economic analysis is to inform 
the decision regarding how and what cost and effect data 
would be collected within a more definitive study. In 
order to inform this decision, we will estimate completion 
rates and seek to identify big cost drivers.
outcome assessment
The primary outcome measure is the proportion of 
eligible patients approached who consent to and comply 
with the trial protocol. This will be assessed by: number of 
eligible patients within the study population and recruit-
ment time frame, percentage of eligible patients accepted 
for randomisation, patient compliance with trial protocol 
measured as per self-reported adherence to interven-
tion and percentage of patients completing study. The 
secondary outcomes include reduction in corneal inflam-
mation (assessed by the Oxford corneal staining guide), 
patient pain and symptoms scores (assessed by the OSDI 
Score) and improvement in objective signs of DED as 
indicated by visual acuity, Schirmer’s test, tear break-up 
time, lower and/or upper tear menisci height measure-
ment. Other secondary end points include patients’ QoL 
(assessed using the EQ-5D-5L Questionnaire), cost to 
the NHS and patient (assessed via use of additional NHS 
services and privately purchased over-the-counter treat-
ments related to DED) and safety measure of pressure 
within the eye (assessed by IOP Score).
data analysis
Detailed data validation will examine completeness, 
existence and accuracy of collected data to assess data 
quality and identify missing and conflicting data. Statis-
tical analysis will be performed on an intention-to-treat 
basis ie, inclusion of patients randomly assigned, regard-
less of adherence, actual treatment received, and subse-
quent withdrawal of treatment and/or deviation from 
the protocol and per-protocol (ie, inclusion of those 
who completed the treatment as planned)29 and will be 
reported according to 2010 CONSORT guidelines.30 All 
statistical analyses will be completed using SPSS Statis-
tics V.22.0.31 A value of p<0.05 will be accepted as statis-
tically significant. Conforming to recommendations for 
feasibility studies, data analysis will be primarily descrip-
tive, with means, SD and frequency counts calculated for 
all variables of interest.
Exploratory efficacy analysis will compare the primary 
outcome variables derived from the data collected at 8 
weeks between the two arms using a marginal general 
linear model with robust standard errors, to allow for clus-
tering by group. Secondary outcomes between the inter-
vention and control groups will be compared at 4 weeks, 
8 weeks and 12 weeks (4 weeks post-treatment). Safety 
outcome measures will include IOP rise and any reported 
infection. Secondary analyses of the primary outcome, 
controlling for baseline covariates, will be performed 
using proportional hazards regression models.32 Analysis 
of treatment discontinuation adjusted for clinical site, 
baseline status, and whether the patient is randomised 
to the FAB or control (conventional treatment only) 
group will be conducted. Any interaction between base-
line status or regimen and treatment will also be assessed. 
Interactions between significant covariates and treatment 
effects will be assessed in the context of the proportional 
hazards models.
Interviews will be recorded, transcribed and analysed 
using the framework analysis. We will structure the anal-
ysis of collected data to fit two evaluation frameworks rele-
vant to the successful implementation of FAB:
 ► Patient-oriented: Understand the lived experience 
of patients using FAB with emphasis on interven-
tion acceptability, perceived enablers and barriers 
for adherence, perceived clarity of advice, and guid-
ance and factors relating to the initial uptake of the 
intervention.
 ► Organisation-oriented: Whether and how the use 
of FAB affected workload and/or workflow; identify 
process change, adaptation challenges, skills gap; 
establish treatment fidelity and clinician acceptability.
study procedures
Informed consent procedures
It is the responsibility of the investigator, or appropriate Good 
Clinical Practice (GCP) trained person delegated by the inves-
tigator as documented in the site delegation log, to obtain 
written informed consent from each participant prior to any 
participation/study-specific procedures. This should follow 
adequate explanation of the aims, methods, anticipated 
benefits and potential hazards of the study. The participants 
will be given ample time to consider giving their consent for 
the study. For this study a minimum of 24 hours will be given 
during which the consenting team will be contactable over 
the phone to answer any questions. The date on which the 
participant information sheet (PIS) is given to the participant 
must be documented within the patient’s notes to confirm 
that sufficient time was given. The investigator (or other qual-
ified person) will explain to the potential participant that they 
are free to refuse any involvement with the study or alterna-
tively withdraw their consent at any point during the study 
and for any reason. If there is any further safety information 
which may result in significant changes in the risk/benefit 
analysis, the PIS and informed consent form (ICF) will be 
reviewed and updated accordingly. All participants that are 
actively enrolled on the study will be informed of the updated 
information and given a revised copy of the PIS/ICF in order 
to confirm their wish to continue on the study.
Screening procedures
Patients will have undergone the below procedures as per 
standard of care which will in turn feed in to the investi-
gator for their review prior to approaching the potential 
participant.
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 ► OSDI Score >33; or
 ► Oxford corneal staining grade ≥2; or
 ► Schirmer's test without anaesthesia <5 mm at 5 min.
The results from these will be reviewed by the investi-
gator prior to approaching the potential participant.
Randomisation procedures
Randomisation will be carried out by the Anglia Ruskin 
Clinical Trials Unit (ARCTU) using the SEALED ENVE-
LOPE randomisation service. SEALED ENVELOPE is a 
randomisation and online database service developed for 
clinical trial services. It is an internet-based system and 
will be set for this study by ARCTU in accordance with the 
protocol. Enrolled patients will undergo 1:1 block rando-
misation to Arm A or Arm B. The system stores the prede-
termined sequence of randomisation and this list is visible 
to neither the investigator nor the ARCTU staff. Once a 
patient has consented to take part in the trial, they will be 
randomly allocated either to Arm A to receive FAB and 
conventional therapy or to Arm B to receive conventional 
therapy only. The research nurse or fellow or designated 
staff will log on to a web browser application and enter 
the patient’s eligibility factors into the system. The treat-
ment allocation will be sent to the research team who will 
make the necessary arrangements for the patient’s treat-
ment plan.
The treating ophthalmologist in the clinic will prescribe 
and counsel all patients on the correct technique for 
conventional treatment. The unblinded research nurses 
will provide additional training to the patients on the 
method of delivering FAB, including the use of a training 
video. Patients will be advised by the research team to 
inform their ophthalmologist if they have been started on 
any new treatment during the trial period by other clini-
cians or themselves.
End of study definition
The definition of the end of study will be the point where 
the last patient recruited had the last follow-up visit.
Participant withdrawal
Patients will be withdrawn from study based on the 
following:
 ► New diagnosis of infection on finger or eye.
 ► Requesting to be withdrawn for other reasons such as 
inconvenience of increased clinic visits.
 ► Pregnancy after recruitment.
 ► Systemic infection, or systemic antimicrobials for 
infection.
 ► If finger sore from repeated prick and patient does 
not want to use another finger.
Any adverse effects will be reported back to the lead 
investigator at the site and, if necessary, the patients.
notification and reporting AEs or reactions
No serious AEs (SAEs) or complications associated with 
use of FAB in the treatment of ocular disease has been 
reported by the literature. Preliminary results of a pilot 
study conducted by the authors and involving 16 patients 
with DED also demonstrated no adverse effects of using 
FAB in the eye for 2 months.22 Although, we do not 
envisage any SAEs with the intervention in this trial, if an 
AE occurs and is not defined as SERIOUS, the AE will be 
recorded in the study file and the participant followed up 
by the research team. The AE will also be documented 
in the participants’ medical notes (where appropriate) 
and the case report form (CRF). SAEs that are consid-
ered to be ‘related’ and ‘unexpected’ will be reported 
to the sponsor within 24 hours of learning of the event 
and to the main research ethics committee within 15 days 
in line with the required time frame. SAE reporting will 
commence at the start of the trial and up to 4 weeks after 
the intervention.
Patient and public involvement
Patients who participated in a previous pilot (exploratory) 
study conducted by the study authors22 were involved in 
a focus group meeting and provided inputs on research 
design and study procedures. Two of the patients also partic-
ipated in an advisory group for this trial and provided input 
on prioritising the research questions and also reviewed 
the study protocol and participant information resources. 
Patients in this trial will be invited to request study results 
from the research team if interested.
EthICs And dIssEMInAtIon
Participant anonymity will be protected and maintained 
at all times. Information with regards to study participants 
will be kept confidential and managed in accordance with 
the Data Protection Act, NHS Caldicott Guardian, The 
Research Governance Framework for Health and Social 
Care and Research Ethics Committee Approval in the UK. 
Data obtained in the trial will be stored using a unique 
study code, which is non-identifiable and anonymised. 
Patients' personal data will be stored separately and confi-
dentially by the participating sites and will not be entered 
into the trial database. All written information will stored 
in a locked filing cabinet in a locked room. Any web-based 
data will be stored in a secure password-protected and 
encrypted central database at ARCTU. Only individuals 
directly involved with the study will have access to trial 
data. Study participants will also be provided with the 
contact details of the trial team at the respective sites who 
will be able to answer any additional queries.
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